Research on the Heart-Brain Coupling Mechanisms and Interventions for Emotional Inhibitory Control Deficits in Individuals With Alcohol Use Disorder

NCT ID: NCT07036055

Last Updated: 2025-06-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-03-15
• Study Completion Date: 2024-08-31

Brief Summary

The goal of this clinical trial is to understand whether combining transcutaneous auricular vagus nerve stimulation (taVNS) with mindfulness training can improve emotional inhibitory control in adults with Alcohol Use Disorder (AUD). The study also aims to explore the brain-heart coupling mechanisms underlying these control deficits.

The main questions it aims to answer are:

Do individuals with AUD have abnormal brain-heart coupling associated with impaired emotional inhibitory control? Can taVNS combined with mindfulness training enhance emotional inhibitory control in individuals with AUD compared to sham stimulation? Researchers will compare a group receiving taVNS plus mindfulness training to a group receiving sham stimulation plus mindfulness training to see whether the active intervention improves behavioral performance and brain-heart coupling.

Participants will:

Complete an emotional Go/NoGo task while EEG and ECG data are recorded Receive 10 days of either real or sham taVNS combined with mindfulness training Complete questionnaires and cognitive assessments before and after the intervention

Detailed Description

This two-part clinical study investigates the mechanisms and intervention effects related to emotional inhibitory control deficits in individuals with Alcohol Use Disorder (AUD), with a specific focus on brain-heart coupling (also referred to as brain-heart interplay, BHI). The study aims to identify the neurophysiological characteristics underlying inhibitory control impairments in AUD and evaluate whether non-invasive vagus nerve stimulation combined with mindfulness training can enhance emotional regulation and cognitive function.

Study 1: Mechanism Exploration Study 1 adopts a case-control observational design. A total of 28 individuals diagnosed with AUD (based on DSM-5 criteria) and 28 age- and education-matched healthy controls are recruited. Participants complete an emotional Go/NoGo task under EEG-ECG hyperscanning. Emotional inhibitory control performance is assessed through behavioral indices (reaction time, error rate) and further analyzed using the Hierarchical Drift Diffusion Model (HDDM) to quantify latent cognitive processing parameters (e.g., drift rate, boundary separation, non-decision time). Brain-heart coupling is evaluated through resting-state EEG-ECG data using multiscale coupling coefficients and maximal information coefficient (MIC) between heart rate variability (HRV) and cortical oscillations (particularly α, β, and θ bands).

Primary outcomes include:

Drift rate and inhibitory control accuracy under emotional interference Degree of BHI (HRV-EEG coupling strength and directionality) The moderating effect of self-reported emotion regulation ability (measured via DERS)

Study 2: Intervention Evaluation

Study 2 is a single-blind randomized controlled trial (RCT) involving 60 AUD participants randomly assigned to:

Active group (n=30): taVNS combined with mindfulness training Control group (n=30): sham stimulation combined with mindfulness training Participants in both groups receive daily 30-minute sessions for 10 consecutive days. taVNS is delivered using a wearable ear-clip device targeting the auricular branch of the vagus nerve (cymba conchae), with stimulation parameters set at 25 Hz, pulse width of 200 μs, and intensity adjusted to individual sensory threshold. Mindfulness training is conducted by a trained therapist, focusing on breath awareness and body scanning.

Outcome measures are collected pre- and post-intervention and include:

Emotional inhibitory control performance under the Go/NoGo paradigm HDDM-derived cognitive parameters (e.g., drift rate) EEG-ECG-based BHI metrics (HRV-EEG coupling during rest) Self-reported anxiety (GAD-7), depressive symptoms (PHQ-9), and alcohol craving Adverse events monitoring and adherence logs Data Acquisition and Processing EEG signals are recorded using a 64-channel portable system (10-20 system); ECG is simultaneously recorded.

Signals are preprocessed in EEGLAB (bandpass filtering, artifact correction via ASR), with HRV features extracted via Kubios.

HDDM modeling is conducted in Python (Bayesian MCMC estimation), and BHI is analyzed through mutual information, MIC, and transfer entropy metrics.

Sample Size and Statistical Plan Sample size was estimated based on prior effect sizes observed in similar taVNS and mindfulness interventions. Power analysis indicated 28 subjects per group achieves >80% power to detect moderate group × time interaction effects.

Statistical analyses include:

Mixed-effects ANOVA for behavioral and neural outcomes Regression models to assess mediation and moderation effects (e.g., emotion regulation ability) Pearson/Spearman correlation between physiological and behavioral measures All analyses follow intention-to-treat principles with imputation for missing data where appropriate (e.g., multiple imputation for <10% missing).

Conditions

Alcohol Use Disorder (AUD)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

taVNS + Mindfulness Training

Participants in this group will receive 30-minute daily sessions of transcutaneous auricular vagus nerve stimulation (taVNS) combined with standardized mindfulness training for 10 consecutive days. taVNS is delivered using a wearable device targeting the cymba conchae area of the ear. Stimulation parameters include a frequency of 25 Hz and a pulse width of 200 µs. Mindfulness training involves guided audio practice focused on breath awareness and body scanning.

Group Type: EXPERIMENTAL

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

Intervention Type: DEVICE

Participants receive transcutaneous auricular vagus nerve stimulation (taVNS) via a non-invasive ear-clip device targeting the cymba conchae. The device delivers electrical pulses at 25 Hz frequency with a pulse width of 200 µs, for 30 minutes daily over 10 consecutive days. The stimulation intensity is individually adjusted to the participant's perceptual threshold. taVNS is paired with standardized mindfulness training in this arm.

Mindfulness Training

Intervention Type: BEHAVIORAL

Participants receive instructor-led mindfulness training conducted by a trained therapist. Each session lasts 30 minutes and focuses on breath awareness, body scanning, and non-judgmental awareness of internal experience. All participants (both taVNS and sham groups) receive this training daily for 10 consecutive days.

Sham Stimulation + Mindfulness Training

Participants in this group will receive 30-minute daily sessions of sham stimulation (identical device without active current) combined with the same mindfulness training protocol as the experimental group, administered for 10 consecutive days. The sham stimulation mimics the appearance and procedure of active taVNS but delivers no electrical stimulation.

Group Type: SHAM_COMPARATOR

Sham Stimulation

Intervention Type: DEVICE

Participants in this group use the same device as in the active taVNS condition, but the stimulation is deactivated. The ear-clip device is placed identically on the cymba conchae, with no electrical current delivered. This sham procedure mimics the look and feel of taVNS but serves as a placebo control. Sham stimulation is combined with the same mindfulness training as the experimental group.

Mindfulness Training

Intervention Type: BEHAVIORAL

Participants receive instructor-led mindfulness training conducted by a trained therapist. Each session lasts 30 minutes and focuses on breath awareness, body scanning, and non-judgmental awareness of internal experience. All participants (both taVNS and sham groups) receive this training daily for 10 consecutive days.

Interventions

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

Participants receive transcutaneous auricular vagus nerve stimulation (taVNS) via a non-invasive ear-clip device targeting the cymba conchae. The device delivers electrical pulses at 25 Hz frequency with a pulse width of 200 µs, for 30 minutes daily over 10 consecutive days. The stimulation intensity is individually adjusted to the participant's perceptual threshold. taVNS is paired with standardized mindfulness training in this arm.

Intervention Type: DEVICE

Sham Stimulation

Participants in this group use the same device as in the active taVNS condition, but the stimulation is deactivated. The ear-clip device is placed identically on the cymba conchae, with no electrical current delivered. This sham procedure mimics the look and feel of taVNS but serves as a placebo control. Sham stimulation is combined with the same mindfulness training as the experimental group.

Intervention Type: DEVICE

Mindfulness Training

Participants receive instructor-led mindfulness training conducted by a trained therapist. Each session lasts 30 minutes and focuses on breath awareness, body scanning, and non-judgmental awareness of internal experience. All participants (both taVNS and sham groups) receive this training daily for 10 consecutive days.

Intervention Type: BEHAVIORAL

Other Intervention Names

taVNS; Auricular Vagus Nerve Stimulation; Mindfulness Meditation; Guided Mindfulness Practice

Eligibility Criteria

Inclusion Criteria

1. Meets DSM-5 diagnostic criteria for Alcohol Use Disorder (AUD).

2. Aged 18-55 years.

3. Currently in the post-acute withdrawal phase (≥2 weeks since last alcohol use).

4. No severe psychiatric comorbidities (e.g., schizophrenia, bipolar disorder).

5. No neurological disorders (e.g., epilepsy, traumatic brain injury).

6. Willing to provide informed consent.

Exclusion Criteria

1. Dependence on other substances (except nicotine).

2. Severe physical illness requiring immediate treatment.

3. Active infectious diseases (e.g., HIV, hepatitis).

4. Inability to complete study procedures (e.g., cognitive impairment).

*(For healthy controls in Study 1, inclusion required AUDIT score ≤8, no psychiatric/neurological history, and matched demographics.)*

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Mental Health Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jiang Du, M.D

Role: STUDY_CHAIR

Shanghai Mental Health Center

Locations

China

Mengzi, Yunnan, China

Countries

China

Other Identifiers

JDu-015

Identifier Type: -

Identifier Source: org_study_id